



## Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

Feb 24, 2026

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn<sup>®</sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the TD Cowen 46<sup>th</sup> Annual Health Care Conference and The Citizens Life Sciences Conference. With an initial focus in oncology, Foghorn's Gene Traffic Control<sup>®</sup> platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

### TD Cowen 46th Annual Health Care Conference

- Presentation: Tuesday, March 3, 2026, at 11:10 a.m. EDT
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Registration Link: [Register here](#)
- Management will also participate in one-on-one meetings

### The Citizens Life Sciences Conference

- Presentation: Wednesday, March 11, 2026, at 11:20 a.m. EDT
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings

A webcast of the TD Cowen presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website, [www.foghorntx.com](http://www.foghorntx.com), and will be available for 90 days.

### About Foghorn Therapeutics

Foghorn<sup>®</sup> Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control<sup>®</sup> platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at [www.foghorntx.com](http://www.foghorntx.com) for more information on the Company, and follow us on [X](#) and [LinkedIn](#).

### Contact:

Karin Hellsvik, Foghorn Therapeutics Inc.  
[khellsvik@foghorntx.com](mailto:khellsvik@foghorntx.com)